On September 1, Huimei SCI-TECH(Huimei), a medical technology company, completed $30 million C round of financing. This round of financing was led by Qiming Venture Partners, followed by Wuxi Apptec and Huimei Capital.
Huimei will use the funding to develop AI medical quality control system.
Founded in 2015, Huimei focuses on the deep mining of healthcare big data, as well as the research and development of AI medical products and clinical application. The company is committed to building "AI-based medical quality control system".
Dr. Mayson is a product of Huimei. It's an AI medical treatment solution focused on improving clinical quality. Dr. Mayson has "single disease process quality management system" and "clinical decision support system (CDSS)". They can use deep learning and other AI technologies to process clinical big data and assist doctors in diagnosis and treatment, so as to help doctors make correct treatment decisions and provide reliable data for management and evaluation.
“We are delighted to have the opportunity to invest in Huimei. Huimei’s latest knowledge and understanding of clinical diagnosis, as well as the capabilities of AI-based technologies, will improve the quality and efficiency of medical services. We will support Huimei in realizing their vision,” said Hu xubo, managing partner of Qiming Venture Capital.
About Qiming Venture Partners
Founded in 2006, Qiming Venture Partners is a China-based venture capital firm specialized in building new companies in China.
About Wuxi Apptec Fund
Founded in 2000, Wuxi Apptec is a global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
About Huimei Capital
Huimei capital is the venture capital department of Huimei company.
渝公网安备 50011202502165号
